Dr. Angélique Bordey Joins Cassava To Advance Preclinical Studies In Tuberous Sclerosis Complex

Cassava Sciences, Inc., a clinical-stage biotechnology company developing new investigational treatments for disorders of the central nervous system, has announced the appointment of Dr. Angélique Bordey as Senior Vice President, Neuroscience. Dr. Bordey will oversee the company’s research and development activities, with a focus on advancing the preclinical evaluation of simufilam for TSC-related epilepsy and exploring its potential use in other pipeline programs.

Rick Barry, President and Chief Executive Officer of Cassava, mentioned, “We are thrilled to have Dr. Angélique Bordey join us. Dr. Bordey will be a tremendous boost to Cassava’s efforts to transform the treatment paradigm for TSC-related epilepsy. Her research, published in Neuron and Science Translational Medicine, was the cornerstone of the recently granted patent that includes the use of simufilam to treat TSC-related epilepsy. Cassava’s subsequent license agreement with Yale University for that patent opens the door to explore this potential indication for simufilam. We believe that Dr. Bordey’s unique neuroscience expertise can be instrumental to advancing our preclinical program and that her stature as a leader in the TSC community may allow for productive study collaborations.”

“Through my academic research and collaboration with the TSC Alliance, I have learned that TSC-related epilepsy is among the more challenging epilepsy syndromes to manage, often requiring innovative and individualized treatment approaches. It is exciting to work directly with the Cassava team to advance the evaluation of simufilam as a potential novel treatment for this devastating rare disease. I am hopeful that simufilam’s unique mechanism of action will provide a new approach to treating TSC-related epilepsy,” commented Dr. Angélique Bordey, SVP, Neuroscience of Cassava.

In addition to her new role at Cassava, Dr. Bordey will continue her academic work on a part-time basis at Yale School of Medicine, where she currently serves as Vice Chair of the Department of Neurosurgery and holds the Rothberg Endowed Chair. She will scale back her responsibilities at Yale to dedicate more time to her position at Cassava Sciences.